Published in Blood on October 01, 1996
IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J (1998) 2.99
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev (1997) 1.57
Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediators Inflamm (2001) 1.17
Interleukin-10 provides direct trophic support to neurons. J Neurochem (2009) 1.14
Improved survival, vascular differentiation and wound healing potential of stem cells co-cultured with endothelial cells. PLoS One (2011) 0.98
Fetal-maternal alignment of regulatory T cells correlates with IL-10 and Bcl-2 upregulation in pregnancy. J Immunol (2013) 0.86
Anti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous Leukemia. PLoS One (2016) 0.83
Sleepless latency of human cytomegalovirus. Med Microbiol Immunol (2015) 0.81
IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion. Clin Immunol (2014) 0.80
Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus. Front Microbiol (2016) 0.79
Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology. World J Stem Cells (2017) 0.78
Latent infection of myeloid progenitors by human cytomegalovirus protects cells from FAS-mediated apoptosis through the cellular IL-10/PEA-15 pathway. J Gen Virol (2015) 0.78
TNF Accelerates Death of Mandibular Condyle Chondrocytes in Rats with Biomechanical Stimulation-Induced Temporomandibular Joint Disease. PLoS One (2015) 0.76
IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans. JCI Insight (2016) 0.76
miR-9 plays a role in IL-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. Cancer Sci (2017) 0.75
Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. J Innate Immun (2016) 0.75
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. Cancer Biol Ther (2016) 0.75
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia (2011) 2.20
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 2.08
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br J Dermatol (1998) 2.08
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol (1985) 1.86
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood (1992) 1.81
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant (2011) 1.73
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia (2005) 1.70
[Polyneuropathy following methaqualone (preliminary note)]. Nervenarzt (1973) 1.64
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood (1997) 1.61
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol (1984) 1.54
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther (2012) 1.47
A new Puumala hantavirus subtype in rodents associated with an outbreak of Nephropathia epidemica in South-East Germany in 2004. Epidemiol Infect (2006) 1.43
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer (1997) 1.41
An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant (1996) 1.38
Fermi observations of high-energy gamma-ray emission from GRB 080916C. Science (2009) 1.37
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med (1985) 1.37
Retracted Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. J Clin Invest (1989) 1.37
Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant (2005) 1.37
[Methodological openness as the basis of integrative psychotherapy]. Psychother Psychosom Med Psychol (2000) 1.34
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant (2004) 1.34
Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood (1989) 1.33
Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. Blood (1987) 1.31
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer (2001) 1.30
How much blood is needed? Vox Sang (2011) 1.30
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia (2003) 1.30
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant (2009) 1.29
IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett (1996) 1.29
Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs (1995) 1.29
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer (1996) 1.26
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia (2011) 1.24
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia (2012) 1.23
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother (2000) 1.22
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol (2005) 1.21
A limit on the variation of the speed of light arising from quantum gravity effects. Nature (2009) 1.20
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood (1995) 1.19
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clin Immunol Immunopathol (1987) 1.19
OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. J Immunol (1983) 1.19
Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood (1980) 1.18
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol (1996) 1.17
Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res (1990) 1.16
Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest (1985) 1.15
Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A (1986) 1.14
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol (1996) 1.13
Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood (1983) 1.11
Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology (1986) 1.09
[Clarithromycin for monotherapy of B-cell MALT lymphoma?]. Ophthalmologe (2013) 1.08
Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cell Immunol (1984) 1.07
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant (2009) 1.07
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood (1990) 1.07
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol (2007) 1.06
Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant (2007) 1.06
Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol (1983) 1.06
Correlation between physical performance and fatigue in cancer patients. Ann Oncol (1997) 1.05
Autologous and allogeneic mixed-lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2, and a prostaglandin inhibitor, WY-18251. Clin Immunol Immunopathol (1984) 1.04
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis (2001) 1.02
Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes. Blood (1989) 1.01
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Human interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiology (1986) 1.00
BCL-2 induction is part of the strategy of Epstein-Barr virus. Leuk Lymphoma (1994) 1.00
Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant (2004) 1.00
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia (2011) 0.99
Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother (1999) 0.99
The acute monocytic leukemias: multidisciplinary studies in 45 patients. Medicine (Baltimore) (1980) 0.99
The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma (1998) 0.99
Gallbladder metastasis from renal cell carcinoma mimicking acute cholecystitis. Eur J Med Res (2009) 0.99
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res (1994) 0.98
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant (2009) 0.98
Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol (1999) 0.98
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer (1991) 0.98
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood (1997) 0.97
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood (1990) 0.97
Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann Hematol (2003) 0.97
A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia (2009) 0.97
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol (1995) 0.97